Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
38 hedge funds and large institutions have $119M invested in Talis Biomedical Corporation Common Stock in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 11 closing their positions.
525% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $342K
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
12% less funds holding
Funds holding: 43 → 38 (-5)
35% less capital invested
Capital invested by funds: $184M → $119M (-$64.7M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$399K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$396K |
| 3 |
JP Morgan Chase
New York
|
+$363K |
| 4 |
State Street
Boston,
Massachusetts
|
+$290K |
| 5 |
PP
PDT Partners
New York
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$4.01M |
| 2 |
Morgan Stanley
New York
|
-$1.13M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.1M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$730K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$527K |
TLIS Hedge Fund Activity: Q3 2021 in Review
38 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q3 2021, worth a combined $119M — down 35% from $184M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TLIS and 7 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 16 added.
The largest buyer was Geode Capital Management, adding an estimated $399K. The largest seller was Redmile Group, exiting entirely with an estimated $4.01M sold.
- 38 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q3 2021, down from 43 in Q2 2021.
- Funds reported $119M of Talis Biomedical Corporation Common Stock stock for Q3 2021, down 35% quarter-over-quarter.
- 7 funds opened new Talis Biomedical Corporation Common Stock positions in Q3 2021 and 11 closed out, a net change of -4 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q3 2021 was Geode Capital Management, an estimated $399K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q3 2021 was Redmile Group, an estimated $4.01M sold.
Based on aggregated 13F filings for Q3 2021.